219 related articles for article (PubMed ID: 36339006)
61. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma.
Shao D; Li Y; Wu J; Zhang B; Xie S; Zheng X; Jiang Z
Front Genet; 2022; 13():903117. PubMed ID: 35692827
[No Abstract] [Full Text] [Related]
62. Identification of m6A/m5C/m1A-associated LncRNAs for prognostic assessment and immunotherapy in pancreatic cancer.
Huang Y; Zhang W; Li Q; Wang Z; Yang X
Sci Rep; 2023 Mar; 13(1):3661. PubMed ID: 36871072
[TBL] [Abstract][Full Text] [Related]
63. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma.
Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y
Front Surg; 2022; 9():860806. PubMed ID: 35937602
[TBL] [Abstract][Full Text] [Related]
64. Development and Validation of an Immune-Related lncRNA Signature for Predicting the Prognosis of Hepatocellular Carcinoma.
Kong W; Wang X; Zuo X; Mao Z; Cheng Y; Chen W
Front Genet; 2020; 11():1037. PubMed ID: 33101369
[TBL] [Abstract][Full Text] [Related]
65. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.
Li G; Liu Y; Zhang Y; Xu Y; Zhang J; Wei X; Zhang Z; Zhang C; Feng J; Li Q; Wang G
Front Immunol; 2022; 13():929089. PubMed ID: 35874689
[TBL] [Abstract][Full Text] [Related]
66. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
[No Abstract] [Full Text] [Related]
67. Eight key long non-coding RNAs predict hepatitis virus positive hepatocellular carcinoma as prognostic targets.
Huang ZL; Li W; Chen QF; Wu PH; Shen LJ
World J Gastrointest Oncol; 2019 Nov; 11(11):983-997. PubMed ID: 31798779
[TBL] [Abstract][Full Text] [Related]
68. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
Tang P; Qu W; Wang T; Liu M; Wu D; Tan L; Zhou H
Front Genet; 2021; 12():785185. PubMed ID: 34917132
[No Abstract] [Full Text] [Related]
69. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.
Chen QF; Li W; Wu PH; Shen LJ; Huang ZL
World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872
[TBL] [Abstract][Full Text] [Related]
70. N7-Methylguanosine-Related lncRNAs: Integrated Analysis Associated With Prognosis and Progression in Clear Cell Renal Cell Carcinoma.
Ming J; Wang C
Front Genet; 2022; 13():871899. PubMed ID: 35495133
[TBL] [Abstract][Full Text] [Related]
71. Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma.
Wang X; Qian J; Yao N; Pocha C; Kang KJ; Angelico R; Zhu G
Ann Transl Med; 2022 May; 10(10):595. PubMed ID: 35722420
[TBL] [Abstract][Full Text] [Related]
72. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
73. A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer.
Luo J; Peng J; Xiao W; Huang S; Cao Y; Wang T; Wang X
Front Genet; 2022; 13():984696. PubMed ID: 36092933
[No Abstract] [Full Text] [Related]
74. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
75. Identification and Validation of Hypoxia-Related lncRNA Signature as a Prognostic Model for Hepatocellular Carcinoma.
Zhou C; Zhang H; Lu L
Front Genet; 2021; 12():744113. PubMed ID: 34650600
[TBL] [Abstract][Full Text] [Related]
76. M7G methylated core genes (METTL1 and WDR4) and associated RNA risk signatures are associated with prognosis and immune escape in HCC.
Li R; Liu X; Deng K; Wang X
BMC Med Genomics; 2023 Aug; 16(1):179. PubMed ID: 37528384
[TBL] [Abstract][Full Text] [Related]
77. Identification of a novel four-lncRNA signature as a prognostic indicator in cirrhotic hepatocellular carcinoma.
Ma L; Deng C
PeerJ; 2019; 7():e7413. PubMed ID: 31396449
[TBL] [Abstract][Full Text] [Related]
78. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
Huang S; Zhang J; Lai X; Zhuang L; Wu J
Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
[No Abstract] [Full Text] [Related]
79. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.
Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
Front Immunol; 2022; 13():914577. PubMed ID: 35757739
[TBL] [Abstract][Full Text] [Related]
80. Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature.
Zhang Z; Shang J; Hu B; Shi H; Cao Y; Li J; Jiao T; Zhang W; Lu S
Front Immunol; 2022; 13():836576. PubMed ID: 35812396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
